Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 127, Issue 15
April 14 2016
Issue Cover

Table of Contents

BLOOD FLASHBACK

McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. Blood. 1959;14(5):503-521.
View Articletitled, McFarland W, Granville NB, Dameshek W. Autologous bone marrow infusion as an adjunct in therapy of malignant disease. <em>Blood</em>. 1959;14(5):<span class="related-article">503-521</span>.

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Deeper understanding of carboxylase
James H. Morrissey
View Articletitled, Deeper understanding of carboxylase
INSIDE BLOOD COMMENTARY
How to avoid being eaten: a lymphoma’s defense
Nora Heisterkamp
View Articletitled, How to avoid being eaten: a lymphoma’s defense
INSIDE BLOOD COMMENTARY
Genetic basis of ethnic disparities in VTE risk
Nigel S. Key,Alex P. Reiner
View Articletitled, Genetic basis of ethnic disparities in VTE risk

PLENARY PAPER

THROMBOSIS AND HEMOSTASIS
Characterization of vitamin K–dependent carboxylase mutations that cause bleeding and nonbleeding disorders
Jian-Ke Tie,Jorge D. A. Carneiro,Da-Yun Jin,Ciro D. Martinhago,Cees Vermeer,Darrel W. Stafford
View Articletitled, Characterization of vitamin K–dependent carboxylase mutations that cause bleeding and nonbleeding disorders
Supplemental data

REVIEW ARTICLE

Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to KLF1 variants
Andrew Perkins,Xiangmin Xu,Douglas R. Higgs,George P. Patrinos,Lionel Arnaud,James J. Bieker,Sjaak Philipsen,the KLF1 Consensus Workgroup
View Articletitled, Krüppeling erythropoiesis: an unexpected broad spectrum of human red blood cell disorders due to <em>KLF1</em> variants
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Clinical Trials & Observations
Nitin Jain,Audrey V. Lamb,Susan O’Brien,Farhad Ravandi,Marina Konopleva,Elias Jabbour,Zhuang Zuo,Jeffrey Jorgensen,Pei Lin,Sherry Pierce,Deborah Thomas,Michael Rytting,Gautam Borthakur,Tapan Kadia,Jorge Cortes,Hagop M. Kantarjian,Joseph D. Khoury
View Articletitled, Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Supplemental data
The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib
Clinical Trials & Observations
Wendy T. Parker,David T. O. Yeung,Alexandra L. Yeoman,Haley K. Altamura,Bronte A. Jamison,Chani R. Field,J. Graeme Hodgson,Stephanie Lustgarten,Victor M. Rivera,Timothy P. Hughes,Susan Branford
View Articletitled, The impact of multiple low-level <em>BCR-ABL1</em> mutations on response to ponatinib
Supplemental data

HEMATOPOIESIS AND STEM CELLS

PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression
Brief Report
Christelle Vincent-Fabert,Nadine Platet,Amelle Vandevelde,Mathilde Poplineau,Myriam Koubi,Pascal Finetti,Guillaume Tiberi,Anne-Marie Imbert,François Bertucci,Estelle Duprez
View Articletitled, PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression
Supplemental data

IMMUNOBIOLOGY

Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms
Jacquelyn M. Lykken,Mayuka Horikawa,Veronique Minard-Colin,Masahiro Kamata,Tomomitsu Miyagaki,Jonathan C. Poe,Thomas F. Tedder
View Articletitled, Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms

LYMPHOID NEOPLASIA

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Bruno Paiva,Luis A. Corchete,Maria-Belen Vidriales,Noemi Puig,Patricia Maiso,Idoia Rodriguez,Diego Alignani,Leire Burgos,Maria-Luz Sanchez,Paloma Barcena,Maria-Asuncion Echeveste,Miguel T. Hernandez,Ramón García-Sanz,Enrique M. Ocio,Albert Oriol,Mercedes Gironella,Luis Palomera,Felipe De Arriba,Yolanda Gonzalez,Sarah K. Johnson,Joshua Epstein,Bart Barlogie,Juan José Lahuerta,Joan Blade,Alberto Orfao,María-Victoria Mateos,Jesús F. San Miguel,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups,on behalf of Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups
View Articletitled, Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
Supplemental data
Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies
Brief Report
Cristina Mirantes,Maria Alba Dosil,David Hills,Jian Yang,Núria Eritja,Maria Santacana,Sònia Gatius,Felip Vilardell,Alexander Medvinsky,Xavier Matias-Guiu,Xavier Dolcet
View Articletitled, Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies
Supplemental data

MYELOID NEOPLASIA

Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy
Y. Lucy Liu,Yan Yan,Cody Webster,Lijian Shao,Shelly Y. Lensing,Hongyu Ni,Wei Feng,Natalia Colorado,Rupak Pathak,Zhifu Xiang,Martin Hauer-Jensen,Shaoguang Li,Daohong Zhou,Peter D. Emanuel
View Articletitled, Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy
Supplemental data

THROMBOSIS AND HEMOSTASIS

Novel genetic predictors of venous thromboembolism risk in African Americans
Wenndy Hernandez,Eric R. Gamazon,Erin Smithberger,Travis J. O’Brien,Arthur F. Harralson,Matthew Tuck,April Barbour,Rick A. Kittles,Larisa H. Cavallari,Minoli A. Perera
View Articletitled, Novel genetic predictors of venous thromboembolism risk in African Americans
Supplemental data

TRANSPLANTATION

Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells
Anne Schönle,Frederike A. Hartl,Jan Mentzel,Theresa Nöltner,Katharina S. Rauch,Alessandro Prestipino,Sebastian A. Wohlfeil,Petya Apostolova,Anne-Kathrin Hechinger,Wolfgang Melchinger,Kerstin Fehrenbach,Marta C. Guadamillas,Marie Follo,Gabriele Prinz,Ann-Katrin Ruess,Dietmar Pfeifer,Miguel Angel del Pozo,Annette Schmitt-Graeff,Justus Duyster,Keli I. Hippen,Bruce R. Blazar,Kristina Schachtrup,Susana Minguet,Robert Zeiser
View Articletitled, Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells
Supplemental data

BLOOD WORK

Delayed diagnosis of MYH-9–related disorder and the role of light microscopy in congenital macrothrombocytopenias
Juliana Perez Botero,Mrinal M. Patnaik
View Articletitled, Delayed diagnosis of <em>MYH-9</em>–related disorder and the role of light microscopy in congenital macrothrombocytopenias

ERRATA

Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5):640-650.
View Articletitled, Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. <em>Blood.</em> 2015;126(5):640-650.
All Issues

Advertisement intended for health care professionals

Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma
Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome in Haploidentical Transplantation
Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation
Prothrombotic Antibodies Targeting the Spike Protein's Receptor-Binding Domain in Severe COVID-19
The Contribution of the Monocyte‐Macrophage Lineage to Immunotherapy Outcomes

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals